Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study. 2022

Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.

To evaluate white matter and grey matter T1-weighted (w)/T2w ratio (T1w/T2w ratio) in healthy controls and patients with multiple sclerosis, and its association with clinical disability. In this cross-sectional study, 270 healthy controls and 434 patients with multiple sclerosis were retrospectively selected from 7 European sites. T1w/T2w ratio was obtained from brain T2w and T1w scans after intensity calibration using eyes and temporal muscle. In healthy controls, T1w/T2w ratio increased until 50-60 years both in white and grey matter. Compared with healthy controls, T1w/T2w ratio was significantly lower in white matter lesions of all multiple sclerosis phenotypes, and in normal-appearing white matter and cortex of patients with relapsing-remitting and secondary progressive multiple sclerosis (p≤0.026), but it was significantly higher in the striatum and pallidum of patients with relapsing-remitting, secondary progressive and primary progressive multiple sclerosis (p≤0.042). In relapse-onset multiple sclerosis, T1w/T2w ratio was significantly lower in white matter lesions and normal-appearing white matter already at Expanded Disability Status Scale (EDSS) <3.0 and in the cortex only for EDSS ≥3.0 (p≤0.023). Conversely, T1w/T2w ratio was significantly higher in the striatum and pallidum for EDSS ≥4.0 (p≤0.005). In primary progressive multiple sclerosis, striatum and pallidum showed significantly higher T1w/T2w ratio beyond EDSS=6.0 (p≤0.001). In multiple sclerosis, longer disease duration, higher EDSS, higher brain lesional volume and lower normalised brain volume were associated with lower lesional and cortical T1w/T2w ratio and a higher T1w/T2w ratio in the striatum and pallidum (β from -1.168 to 0.286, p≤0.040). T1w/T2w ratio may represent a clinically relevant marker sensitive to demyelination, neurodegeneration and iron accumulation occurring at the different multiple sclerosis phases.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D001930 Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits. Brain Lacerations,Acute Brain Injuries,Brain Injuries, Acute,Brain Injuries, Focal,Focal Brain Injuries,Injuries, Acute Brain,Injuries, Brain,Acute Brain Injury,Brain Injury,Brain Injury, Acute,Brain Injury, Focal,Brain Laceration,Focal Brain Injury,Injuries, Focal Brain,Injury, Acute Brain,Injury, Brain,Injury, Focal Brain,Laceration, Brain,Lacerations, Brain
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D020528 Multiple Sclerosis, Chronic Progressive A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914) Chronic Progressive Multiple Sclerosis,Multiple Sclerosis, Progressive Relapsing,Multiple Sclerosis, Remittent Progressive,Multiple Sclerosis, Primary Progressive,Multiple Sclerosis, Secondary Progressive,Primary Progressive Multiple Sclerosis,Progressive Relapsing Multiple Sclerosis,Remittent Progressive Multiple Sclerosis,Secondary Progressive Multiple Sclerosis
D066127 White Matter The region of CENTRAL NERVOUS SYSTEM that appears lighter in color than the other type, GRAY MATTER. It mainly consists of MYELINATED NERVE FIBERS and contains few neuronal cell bodies or DENDRITES. Cerebellar White Matter,Cerebellar White Matters,Matter, Cerebellar White,Matter, White,Matters, Cerebellar White,Matters, White,White Matter, Cerebellar,White Matters,White Matters, Cerebellar

Related Publications

Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
January 2019, Frontiers in neurology,
Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
December 2022, NeuroImage,
Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
December 2021, Multiple sclerosis (Houndmills, Basingstoke, England),
Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
January 2024, Brain structure & function,
Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
November 2021, Scientific reports,
Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
August 2023, Developmental cognitive neuroscience,
Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
January 2022, Frontiers in neurology,
Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
January 2019, Annals of neurology,
Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
February 2017, Proceedings of SPIE--the International Society for Optical Engineering,
Monica Margoni, and Elisabetta Pagani, and Alessandro Meani, and Loredana Storelli, and Sarlota Mesaros, and Jelena Drulovic, and Frederik Barkhof, and Hugo Vrenken, and Eva Strijbis, and Antonio Gallo, and Alvino Bisecco, and Deborah Pareto, and Jaume Sastre-Garriga, and Olga Ciccarelli, and Marios Yiannakas, and Jacqueline Palace, and Paolo Preziosa, and Maria A Rocca, and Massimo Filippi, and
May 2022, Brain sciences,
Copied contents to your clipboard!